%0 Journal Article
%T Resource use and costs of transitioning from paediatric to adult care for patients with chronic endocrine disease.
%A Choukair D
%A Mittnacht J
%A Treiber D
%A Hoffmann GF
%A Grasemann C
%A Huebner A
%A Berner R
%A Burgard P
%A Szendroedi J
%A Bettendorf M
%J Clin Endocrinol (Oxf)
%V 101
%N 2
%D 2024 Aug
%M 38979902
%F 3.523
%R 10.1111/cen.15105
%X <B>OBJECTIVE: </B>Structured transition of adolescents and young adults with a chronic endocrine disease from paediatric to adult care is important. Until now, no data on time and resources required for the necessary components of the transition process and the associated costs are available.<BR><B>METHODS: </B>In a prospective cohort study of 147 patients with chronic endocrinopathies, for the key elements of a structured transition pathway including (i) assessment of patients' disease-related knowledge and needs, (ii) required education and counselling sessions, (iii) compiling an epicrisis and a transfer appointment of the patient together with the current paediatric and the future adult endocrinologist resource consumption and costs were determined.<BR><B>RESULTS: </B>One hundred and forty-three of 147 enroled patients (97.3%) completed the transition pathway and were transferred to adult care. The mean time from the decision to start the transition process to the final transfer consultation was 399 ± 159 days. Transfer consultations were performed in 143 patients, including 128 patients jointly with the future adult endocrinologist. Most consultations were performed by a multidisciplinary team consisting of a paediatric and adult endocrinologist, psychologist, nurse, and a social worker acting also as a case manager with a median of three team members and lasted 87.6 ± 23.7 min. The mean cumulative costs per patient of all key elements were 519 ± 206 Euros. In addition, costs for case management through the transition process were 104.8 ± 28.0 Euros.<BR><B>CONCLUSIONS: </B>Using chronic endocrine diseases as an example, it shows how to calculate the time and cost of a structured transition pathway from paediatric to adult care, which can serve as a starting point for sustainable funding for other chronic rare diseases.